Last reviewed · How we verify
EsoDuo® Tablet
EsoDuo® Tablet, marketed by Chong Kun Dang Pharmaceutical, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its established brand and patient base. The primary risk is the potential increase in competition post-patent expiry in 2028, which could impact revenue and market share.
At a glance
| Generic name | EsoDuo® Tablet |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of EsoDuo® (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EsoDuo® Tablet CI brief — competitive landscape report
- EsoDuo® Tablet updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI